Open Access Open Access  Restricted Access Subscription or Fee Access

An Overview of Anticoagulants in Treatment of Thrombosis and Related Disorders: A review

Walli Mohammed, Dr. Hemant Sharma


With the increasing ageing of population, clinicians are encountering patients with atrial fibrillation and venous thromboembolism who require anticoagulant therapy to prevent stroke and systemic embolism. Due to its high prevalence and unfavorable results, the treatment of thromboembolic disease has become a clinically important area. Traditional anticoagulants such as heparin, low molecular weight heparin, and warfarin have been used to prevent and treat venous and arterial thrombosis. However, bleeding problems, parenteral routes of administration, or the need for frequent monitoring due to various reactions limit their use. This article outlines coagulation along with existing treatments available for anticoagulant therapy, starting with naming schemes, strengths, weaknesses, precautions, and contraindications compared to vitamin K, and the new oral anticoagulant (NOAC). Get the latest information on the benefits of and recent advances. Antagonists (VKA) based on various recent studies and clinical trials.


Thrombosis, new oral anticoagulants, venous thromboembolism, venous and arterial thromboembolism

Full Text:



Lorenzo Gervaso, Heloni Dave, Alok A. Khorana, Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review,JACC: CardioOncology, Volume 3, Issue 2, 2021, Pages 173-190, ISSN 2666-0873,

Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. ThrombHaemost 2005a, 93(4), 700-705.

Wolf C R, Smith G, Smith R L. Science, medicine, and the future, Pharmacogenetics. BMJ 2000, 320, 987- 990.

Wolf C R, Smith G. Pharmacogenetics. Br Med Bull 1999, 55, 366-386.

Wadelius M, Chen L Y, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005, 5, 262-270.

Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007a, 121, 23–34.

Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113(4), 784-792.

Wadelius M, Pirmohamed M, Pharmacogenetics of warfarin, current status and future challenges. Pharmacogenomics J 2007b, 7, 99–111. 9.Evans M, Lewis GM, Increase in international normalized ratio after smoking cessation in a patient receiving warfarin. Pharmacotherapy 2005, 25(11), 1656-1659.

Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy, Antithrombotic therapy and prevention of thrombosis, 9th ed, American college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141(2), e691S-736S.

Di Nisio, M., Valeriani, E., Riva, N., Schulman, S., Beyer‐Westendorf, J., & Ageno, W. (2020). Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. Journal of Thrombosis and Haemostasis, 18(7), 1562-1568.

Wintzen, A. R., De Jonge, H., Loeliger, E. A., & Bots, G. T. A. M. (1984). The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 16(5), 553-558.

Hylek, E. M., Skates, S. J., Sheehan, M. A., & Singer, D. E. (1996). An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. New England Journal of Medicine, 335(8), 540-546.

Cannegieter, S. C., Rosendaal, F. R., Wintzen, A. R., Van der Meer, F. J. M., Vandenbroucke, J. P., & Briet, E. (1995). Optimal oral anticoagulant therapy in patients with mechanical heart valves. New England Journal of Medicine, 333(1), 11-17.

Adam, S. S., McDuffie, J. R., Ortel, T. L., & Williams Jr, J. W. (2012). Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Annals of internal medicine, 157(11), 796-807.

Palareti, G., Manotti, C., D’Angelo, A., Pengo, V., Erba, N., Moia, M., ... & ISCOAT Study Group. (1997). Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study. Thrombosis and haemostasis, 78(12), 1438-1443.

Einstein Investigators. (2010). Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine, 363(26), 2499-2510.

Kamali, F., & Pirmohamed, M. (2006). The future prospects of pharmacogenetics in oral anticoagulation therapy. British journal of clinical pharmacology, 61(6), 746-751.

Oldenburg, J., Bevans, C. G., Fregin, A., Geisen, C., Müller-Reible, C., & Watzka, M. (2007). Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thrombosis and haemostasis, 98(09), 570-578.

D’Andrea, G., D’Ambrosio, R., & Margaglione, M. (2008). Oral anticoagulants: Pharmacogenetics: Relationship between genetic and non-genetic factors. Blood reviews, 22(3), 127-140.


Vogel F. Moderne problem der humangenetik. Ergeb Inn Med U Kinderheilk. 1959;12:52–125.

Schafer, A. I., Levine, M. N., Konkle, B. A., & Kearon, C. (2003). Thrombotic disorders: diagnosis and treatment. ASH Education Program Book, 2003(1), 520-539.

Segal, J. B., McNamara, R. L., Miller, M. R., Kim, N., Goodman, S. N., Powe, N. R., ... & Johns Hopkins Evidence‐based Practice Center. (2000). Prevention of thromboembolism in atrial fibrillation: a meta‐analysis of trials of anticoagulants and antiplatelet drugs. Journal of general internal medicine, 15(1), 56-67.

Hart, R. G., Benavente, O., & Pearce, L. A. (1999). Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovascular Diseases, 9(4), 215-217.

Grody, W. W., Griffin, J. H., Taylor, A. K., Korf, B. R., & Heit, J. A. (2001). American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genetics in Medicine, 3(2), 139-148. 27.Bick, R. L., & Kaplan, H. (1998). Syndromes of thrombosis and hypercoagulability: congenital and acquired causes of thrombosis. Medical Clinics of North America, 82(3), 409-458.

EA, L. (1985). ICSH/ICTH recommendation for reporting prothrombin time in oral anticoagulant control. Thromb Haemostas, 53, 155-156.

Goldstein, D. B., Tate, S. K., & Sisodiya, S. M. (2003). Pharmacogenetics goes genomic. Nature Reviews Genetics, 4(12), 937-947.

Kalia, M. (2013). Personalized oncology: Recent advances and future challenges. Metabolism, 62, S11-S14.


  • There are currently no refbacks.

Copyright (c) 2023 Research & Reviews: A Journal of Pharmacology